Updated:
iuvo BioScience
Partner with iuvo Clinical, a specialized CRO dedicated 100% to ophthalmology. We accelerate ophthalmic breakthroughs from concept to commercialization.
iuvo BioScience
Partner with iuvo Clinical, a specialized CRO dedicated 100% to ophthalmology. We accelerate ophthalmic breakthroughs from concept to commercialization. Learn more.
General information
Firm type
Other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Rochester
Corporate office
Rochester, NY, United States
Sector focus
Frequently asked questions
What specific ophthalmology segments does iuvo BioScience cover?
iuvo states it operates across both anterior and posterior segments of ophthalmology. Its expertise spans retinal diseases, ocular devices, and other vision-science indications, positioning it as a full-service partner for a broad range of eye care therapies.
What is iuvo BioScience's track record with FDA approvals?
According to the firm's website, iuvo has supported sponsors in achieving regulatory success for 10 of the 23 FDA-approved ophthalmic drugs since 2008. This track record underscores its involvement in a substantial portion of the recent ophthalmic drug market.
Does iuvo BioScience operate internationally?
Yes, iuvo conducts trials across North America and maintains a global network of investigators for broader studies, though its headquarters and primary operations are based in Rochester, New York. The firm emphasizes retaining the responsiveness of a focused CRO while offering international reach.
What services fall under iuvo BioScience's full-service model?
iuvo manages the entire clinical trial lifecycle, from protocol development and trial design through to final regulatory submission. The firm positions this end-to-end integration as a key advantage, keeping all strategic and operational functions coordinated internally for ophthalmic sponsors.
Who leads iuvo BioScience's operations?
The firm's website directs visitors to a team page, but specific leadership names and professional backgrounds are not available in the current public materials. The company describes its team as experienced professionals dedicated to ophthalmic research, without naming principals or a management committee at this time.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: